Tyrosine kinase inhibitorFDA-approvedSecond-line
Cobimetinib
How it works
Blocks the MEK protein, which is involved in cancer cell growth, allowing the cancer cells to die.
Cancer types
Melanoma— BRAF V600E mutation
Efficacy
In clinical trials, around 50% of patients achieved an objective response, with median progression-free survival of approximately 12.3 months.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Combining Alectinib and Cobimetinib to Treat Advanced Lung Cancer | Lung Cancer | phase-1 | — | Source → |
| Cobimetinib for Chronic Myelomonocytic Leukemia with RAS Pathway Mutations | Leukemia | phase-2 | — | Source → |
| Testing a New Combination Therapy for Advanced Ovarian and Endometrial Cancers | Ovarian Cancer | phase-1 | — | Source → |
| Real-world study of melanoma treatment in Germany | Melanoma | observational | Median overall survival was 21.6 months in patients without brain metastases and 7.4 months in patients with brain metastases. | Source → |
| Cobimetinib Plus Vemurafenib Shows Antitumor Activity in Advanced Solid Tumors | Melanoma | phase-2 | The disease control rate was 68% and the objective response rate was 57%. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.